Search
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalIt is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups. … Prophylactic treatment may dramatically improve the management of severe haemophilia A in the future by reducing joint bleeding and other hemorrhages that cause chronic pain and disability to patients
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalSebetralstat is the first and only oral on-demand treatment for HAE, providing a convenient alternative to injectable therapies that have been challenging for patients to use [L53538, A274293]. … Hereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat [L53533
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPD-0299685
go.drugbank.com/drugs/DB15264InvestigationalPD-0299685 is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause).
Phenobarbital
go.drugbank.com/drugs/DB01174ApprovedInvestigationalIt promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Mixtures: PB Hyos, Re-PB HyosCategories: P-glycoprotein inducers, P-glycoprotein substratesCyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Categories: Antihistamines for Systemic Use, Cytochrome P-450 CYP2C9 InhibitorsDexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. … unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Ethambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisIsoetharine
go.drugbank.com/drugs/DB00221ApprovedIsoetharine is a fast-acting bronchodilator used for emphysema, bronchitis and asthma.[A330]
Categories: Adrenergics for Systemic Use, Drugs for Obstructive Airway DiseasesMexiletine
go.drugbank.com/drugs/DB00379ApprovedInvestigationalIt may have some anticonvulsant properties.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsLorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnLorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. … It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates